Tectonic Therapeutic公司宣布，其候选药物TX2100已获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，用于治疗遗传性出血性毛细血管扩张症（HHT）。与此同时，FDA已为该药物在1b期临床试验中的新药临床研究申请（IND）亮了绿灯。
Tectonic Therapeutic公司宣布，其候选药物TX2100已获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，用于治疗遗传性出血性毛细血管扩张症（HHT）。与此同时，FDA已为该药物在1b期临床试验中的新药临床研究申请（IND）亮了绿灯。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.